Editorial Comment.
Urology, 2016 Sep 9
YOU ARE EXPLORING
Clint Cary, MD, MPH
Assistant Professor of Urology
Bio
Dr. Cary completed his urology residency at Indiana University and then went on to complete a two year urologic oncology fellowship at the University of California, San Francisco. In addition to his fellowship, he completed a Master of Public Health Degree from U.C. Berkeley with a concentration in epidemiology. His clinical interest is in urologic oncology with a focus on the surgical managment of advanced testicular cancer and bladder cancer. His research efforts focus on health services and outcomes research in testis and bladder cancer.
Dr. Cary may be contacted for an appointment by either using the online request link, by phone at (317) 948-9272, by fax at (317) 944-0174
2012
MPH
Public Health, Epidemiology, University of California, Berkeley
2011
FEL
Urologic Oncology Fellowship, University of California, San Francisco
2005
MD
Medicine (M.D.), University of Tennessee
2005
RES
Urology Residency, Indiana University School of Medicine
2001
BS
Biochemistry & Cellular & Molecular Biology, University of Tennessee
Dr. Cary's primary research interest involves testicular cancer. He has published numerous peer-reviewed publications describing the surgical management and outcomes in patients with advanced germ cell tumors. He is currently involved with several projects including a Pilot study in patients with clinical stage I testicular cancer to understand how they make treatment decisions. He is also the site Principal Investigator for the multi-institutional Phase II RPLND trial in patients with early metastatic seminoma.
Additionally, Dr. Cary is funded through the National Cancer Institute by a K23 Career Development Award over 5-years. His grant evaluates patterns of care in patients with non-muscle invasive bladder cancer who received mitomycin C and to develop and implement interventions to improve access to this therapy.
Finally, he is the Director of the Cancer Health Equities Center at the Indiana University Melvin and Bren Simon Cancer Center. In this role, he unites cancer researchers across IU campuses including Purdue and Notre Dame to address cancer health disparities across the state of Indiana through research, policy, and community engagement.
A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy.
The Journal of urology, 2016 Sep 28
Management of Duodenal Involvement During Retroperitoneal Lymph Node Dissection for Germ Cell Tumors.
Urology, 2016 Sep 19
Editorial Comment.
The Journal of urology, 2016 Nov 9
Author Reply.
Urology, 2016 Nov 7
Management of Pelvic Metastases in Patients With Testicular Cancer.
Urology, 2016 Nov 10
Variation in prostate cancer treatment associated with population density of the county of residence.
Prostate cancer and prostatic diseases, 2016 Jan 19
Early detection of prostate cancer: can we have our cake and eat it too?
Expert review of anticancer therapy, 2016 Feb 2
Author Reply.
Urology, 2016 Dec 26
Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
Cancer, 2015 Sep 15
The Evolution and Technique of Nerve-Sparing Retroperitoneal Lymphadenectomy.
The Urologic clinics of North America, 2015 Jun 6
Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection.
Urology, 2015 Jul 29
Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications.
Urologic oncology, 2015 Jan 5
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration.
The Journal of urology, 2015 Dec 31
Risk for Clostridium difficile infection after radical cystectomy for bladder cancer: Analysis of a contemporary series.
Urologic oncology, 2015 Aug 14
American Urologic Association
Dr. Cary's clinical interest is the surgical management of testicular cancer patients including primary and post-chemotherapy RPLND. Additionally, he performs various urinary diversions, including ileal conduit, Indiana Pouch, and neobladder for patients with muscle invasive bladder cancer as well as local and advanced kidney cancer surgery using robotic and open techniques.